cerebral embolism
Conditions
Interventions
Low dose: Bone marrow 25ml On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration (only once per patient). Mononuclear cells are purified by Ficoll and administrated intravenously
Sponsors
National Cerbral and Cardiovascular Center
Institute of Biomedical Research and Innovation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with cerebral embolism. 2. NIHSS score is more than (or equal to) 10. 3. On day 7 after onset of stroke, the improvement of NIHSS is less than (or equal to) 5. 4. Bone marrow aspiration can be done in 10 days after onset of stroke.
Exclusion criteria
Exclusion criteria: 1. Patient with cerebral hemorrhage or symptomatic hemorrhagic infarction. 2. Patient who expects brain surgery. 3. Patient with acute myocardial infarction. 4. Patient with coagulation disorder. 5. Number of Platelet < 100000/mm3 6. Serum creatinine level >2.0mg/dl 7. Patient with malignancy. 8. Patient with uncontrolled proliferative diabetic retinopathy. 9. Patient suspected infective endocarditis. 10. HBV, HCV, HIV or HTLV positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Improvement of NIHSS (before vs 1 month after cell transplantation) 2. Frequency of change for the worse in NIHSS (before vs 1 month after cell transplantation) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. mRS (1, 3 and 6 months after cell transplantation) 2. Barthel Index (1, 3 and 6 months after cell transplantation) 3. NIHSS (1, 3 and 6 months after cell transplantation) 4. Ratio of mRS=0, 1, 2 or 3 at discharge 5. Frequency of hemorrhagic infarction (1 and 6 months after cell transplantation) 6. Frequency of death at discharge | — |
Countries
Japan
Contacts
Public ContactAkihiko Taguchi
National Cerbral and Cardiovascular Center Department of Cerebrovascular Disease
Outcome results
None listed